![](https://ml-eu.globenewswire.com/media/f45ae7a3-4012-4116-92c7-9b91f510a887/small/orion-rgb-png.png)
Inside information: Phase III ARANOTE trial of darolutamide in combination with androgen deprivation therapy in men with ...
ORION CORPORATION STOCK EXCHANGE RELEASE – INSIDE INFORMATION 17 JULY 2024 at 8.30 EEST Inside information: Phase III ARANOTE trial of darolutamide in combination with androgen deprivation therapy in men with metastatic hormone-sensitive …